Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ISAL 2019 | BCL-2 targeting in AML: updates

Marina Konopleva • 25 Feb 2019
ISAL 2019
Acute Myeloid Leukemia Leukemia Cytarabine Venetoclax

Marina Konopleva, MD, PhD, of the University of Texas MD Anderson Cancer Center, Houston, TX, discusses the latest updates in BCL-2 targeting for acute myeloid leukemia (AML) at the International Symposium on Acute Leukemias (ISAL) 2019, held in Munich, Germany. Prof. Konopleva highlights the importance of this therapy for elderly patients who cannot tolerate other therapies, while it also has the potential to be combined with more intensive treatments in younger patients.

Explore the AML Channel banner with headshots of Naval Daver, Eunice Wang, and Thomas Cluzeau

More from Marina Konopleva

Novel targets, combinations, and treatments in AML: insights from iwAL 2026
19:38
Novel targets, combinations, and treatments in AML: insights from iwAL 2026
Gail Roboz et al. • 7 Oct 2026
The value and mission of the International Workshop on Acute Leukemias
14:36
The value and mission of the International Workshop on Acute Leukemias
Charles Craddock et al. • 21 Oct 2025
iwAL 2025 highlights: resistance mechanisms in AML, novel targets, menin inhibitors & more
21:29
iwAL 2025 highlights: resistance mechanisms in AML, novel targets, menin inhibitors & more
Aditi Shastri et al. • 19 Sep 2025
Anti-tumor activity and hematopoietic restoration achieved with tagraxofusp in treatment-naïve BPDCN
1:48
Anti-tumor activity and hematopoietic restoration achieved with tagraxofusp in treatment-naïve BPDCN
Marina Konopleva • 13 Jun 2025

Related Videos

Unmet needs in CLL genomics: heterogeneity and clinical impact
1:11
Unmet needs in CLL genomics: heterogeneity and clinical impact
Elias Campo • 16 Oct 2026
Insights into key topics most likely to impact day-to-day CLL management
1:40
Insights into key topics most likely to impact day-to-day CLL management
Alessandra Ferrajoli • 16 Oct 2026
Translating current CLL evidence into national guidelines: which gaps remain?
3:33
Translating current CLL evidence into national guidelines: which gaps remain?
Mary Ann Anderson • 16 Oct 2026
Frontline management of Richter’s transformation: current approaches and remaining uncertainties
2:40
Frontline management of Richter’s transformation: current approaches and remaining uncertainties
Philip Thompson • 22 Oct 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals